GAiT Follow 573 278
Global Alliance for iPSC Therapies: Developing therapies from clinical-grade induced pluripotent stem cells and supporting expansion of this nascent field.
With a very heavy heart, we announce the passing of our CEO and co-founder, Susan Solomon, following a long battle with ovarian cancer. We owe all that NYSCF has accomplished to Susan, and no words can express our gratitude and awe for her catalytic impact on stem cell research.
Great panel on regulatory futures for CGT from various perspectives - Niloofar Davoodi, @TakedaPharma, Ian Rees, @MHRAgovuk, Michael von Forstner, @biogen and led by Jacqueline Barry, @CGTCatapult
#advancedtherapieseurope #ate2022 #ate22 #celltherapy #regulatory
Companies developing iPSC-based cell therapies
Characterization of advanced therapies: leveraging advanced #analytics to avoid #FDA holds
Find out the key #assay types needed for successful characterization of #cellandgenetherapy
Read the FastFacts poster, or watch the video, here: http://bit.ly/3AxQmMz
GAiT looks forward to speaking to Indian Colleagues from CMC Vellore at the 7th Cell and Gene Therapy Symposium 1st -3rd September 2022. http://www.cscr.res.in/symposium
NYSCF's annual scientific meeting in New York 18-19th October 2022. Speakers list and registration can be accessed at
Program - 2022 NYSCF Conference
Covering a wide range of topics, The NYSCF Conference fosters progress in stem cell research by providing a forum ...
GAiT and CiRA Foundation are grateful for all those organizations who will participate in the 2nd iPSC Quality Assessment Round. We should be in touch with you shortly with extra information.
What is a target product profile (TPP) and why should you have one for you CAR T-cell therapy? A guest blogger from @CCRM_au explains. https://www.signalsblog.ca/target-product-profile-starting-that-journey-of-a-thousand-miles-with-the-right-first-step/